Nvidia GPUs Are Essential for AI Drug Discovery but Not a Determining Factor in Market Leadership
Gevorg Grigoryan, co-founder and CTO of Generate Biomedicines, emphasized that while Nvidia's GPUs are essential for training large-scale models used in drug discovery, they alone do not determine market leadership. In an exclusive interview with Benzinga, he explained that the real competitive edge comes from combining advanced computing power with proprietary biological data, experimental measurement scale, and a feedback loop between AI-generated molecule testing and model refinement. Grigoryan highlighted Generate's approach of using AI to generate molecular candidates, experimentally test them, and feed results back into models for continuous improvement. This iterative process allows the company’s systems to evolve over time in ways that simply increasing GPU power cannot replicate without access to unique data sets. His comments reflect a broader trend where investors are shifting focus from infrastructure alone toward platforms with differentiated AI capabilities. For biotech companies competing in AI-driven drug discovery, Grigoryan's insights suggest the importance of building durable competitive advantages through proprietary datasets and self-improving systems rather than relying solely on access to high-performance computing.
Topics: AI drug discovery competitive advantage in biotech Nvidia GPUs